share_log

Comerica Bank Makes New Investment in ZimVie Inc. (NASDAQ:ZIMV)

Defense World ·  Feb 1, 2023 06:22

Comerica Bank purchased a new stake in shares of ZimVie Inc. (NASDAQ:ZIMV – Get Rating) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 16,019 shares of the company's stock, valued at approximately $110,000. Comerica Bank owned about 0.06% of ZimVie as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the business. US Bancorp DE bought a new stake in shares of ZimVie during the 3rd quarter valued at $36,000. Strs Ohio purchased a new stake in ZimVie in the third quarter worth about $47,000. Allspring Global Investments Holdings LLC bought a new position in shares of ZimVie in the third quarter worth about $71,000. Texas Permanent School Fund purchased a new position in shares of ZimVie during the 3rd quarter valued at about $148,000. Finally, Raymond James & Associates bought a new position in shares of ZimVie during the 3rd quarter valued at approximately $110,000. Institutional investors own 74.29% of the company's stock.

Get ZimVie alerts:

ZimVie Price Performance

Shares of ZIMV stock opened at $9.81 on Wednesday. The stock's 50-day moving average price is $8.97 and its 200-day moving average price is $11.58. ZimVie Inc. has a 12-month low of $6.67 and a 12-month high of $50.40. The company has a quick ratio of 1.48, a current ratio of 2.51 and a debt-to-equity ratio of 0.76.

ZimVie (NASDAQ:ZIMV – Get Rating) last issued its quarterly earnings data on Wednesday, November 9th. The company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.22. ZimVie had a negative return on equity of 2.75% and a negative net margin of 9.96%. The business had revenue of $214.58 million for the quarter, compared to analysts' expectations of $214.83 million. Analysts expect that ZimVie Inc. will post 1.95 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Barclays initiated coverage on shares of ZimVie in a research note on Wednesday, December 21st. They set an "underweight" rating and a $9.00 target price on the stock.

ZimVie Profile

(Get Rating)

ZimVie Inc, a medical technology company, develops, manufactures, and delivers a portfolio of products and solutions designed to treat a range of spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; bone grafts, barrier membranes, allografts, and collagen wound care products; intraoral scanners; and virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and patient-specific restorative components and intra-oral scanners, as well as spinal fusion implants and instrumentation for various spinal procedures, biologics, and bone healing technologies.

Read More

  • Get a free copy of the StockNews.com research report on ZimVie (ZIMV)
  • Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
  • Dividend King Sysco: Buying On The Dip
  • Is the 1,600% Rise in Genius Group Stock Justified?
  • After Further Review, Investors Liked Exxon Mobil's Earnings
  • Will Caterpillar Dig Its Way To Another Buying Opportunity?

Want to see what other hedge funds are holding ZIMV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ZimVie Inc. (NASDAQ:ZIMV – Get Rating).

Receive News & Ratings for ZimVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZimVie and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment